GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-11-30

Study Completion Date

2005-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

NCT00051103

Metastatic Breast Cancer Neoplasms, Breast

COMPLETED PHASE2

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

NCT00095706

Breast Cancer

COMPLETED PHASE1/PHASE2

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

NCT00721630

Breast Cancer

COMPLETED PHASE2

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

NCT00475670

Breast Cancer

COMPLETED PHASE2

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

NCT04556292

Breast Cancer Metastatic BRCA 1 Gene Mutation BRCA 2 Gene Mutation

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms, Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW572016

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed Informed Consent.
* Histologically confirmed Stage IIIb or IV breast cancer.
* Refractory breast cancer defined as progression in the metastatic setting after prior therapy with anthracyclines, taxanes and capecitibine.
* Subjects with documented ErbB2 tumor overexpression must have received at least 6 cycles of trastuzumab.
* Documented disease progression of the most recent treatment is required.
* Archived tumor tissue available for testing.
* Measurable lesions according to Response Evaluation Criteria In Solid Tumors (RECIST).
* At least 3 weeks since prior cancer therapies except for trastuzumab which must be discontinued at least 2 weeks prior to the beginning of study drug.
* Bisphosphonate therapy initiated prior to study entry is allowed, however, initiation of bisphosphonates following study entry is not allowed.
* Able to swallow and retain oral medication.
* Cardiac ejection fraction within the institutional normal range as measured by echocardiogram or MUGA (Multiple Gated Acquisition) scan.
* Adequate kidney and liver function.
* Adequate bone marrow function.

Exclusion Criteria

* Pregnant or lactating.
* Copies of nadir scans and/or photographs of the tumor prior to disease progression as well as scans documenting disease progression are not available for review.
* Malabsorption syndrome, ulcerative colitis, disease significantly affecting gastrointestinal function or resection of the stomach or small bowel.
* History of other malignancy.
* Serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent.
* Active or uncontrolled infection.
* Known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure.
* Known history of or clinical evidence of leptomeningeal carcinomatosis.
* Active infection.
* Concurrent cancer therapy or investigational therapy.
* Use of oral or IV steroids.
* Unresolved or unstable serious toxicity from prior therapy.
* Prior treatment with an ErbB1 and/or ERbB2 inhibitor other than trastuzumab.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No